Nanoform Finland Plc - Asset Resilience Ratio
Nanoform Finland Plc (NANOFH) has an Asset Resilience Ratio of 55.62% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Nanoform Finland Plc's Asset Resilience Ratio has changed over time. Check Nanoform Finland Plc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Nanoform Finland Plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NANOFH market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €32.68 Million | 49.09% |
| Short-term Investments | €4.34 Million | 6.52% |
| Total Liquid Assets | €37.02 Million | 55.62% |
Asset Resilience Insights
- Very High Liquidity: Nanoform Finland Plc maintains exceptional liquid asset reserves at 55.62% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Nanoform Finland Plc Industry Peers by Asset Resilience Ratio
Compare Nanoform Finland Plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
|
INVENTIVA ADS/1 O.N.
F:6IVA |
Biotechnology | 52.73% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
NASDAQ:TRAXV |
Biotechnology | 13.07% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
Annual Asset Resilience Ratio for Nanoform Finland Plc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Nanoform Finland Plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 57.73% | €41.45 Million ≈ $48.46 Million |
€71.81 Million ≈ $83.95 Million |
-3.05pp |
| 2023-12-31 | 60.78% | €47.49 Million ≈ $55.52 Million |
€78.13 Million ≈ $91.35 Million |
-7.23pp |
| 2022-12-31 | 68.02% | €68.45 Million ≈ $80.03 Million |
€100.64 Million ≈ $117.66 Million |
-7.92pp |
| 2021-12-31 | 75.94% | €75.45 Million ≈ $88.21 Million |
€99.35 Million ≈ $116.15 Million |
-6.26pp |
| 2020-12-31 | 82.19% | €60.73 Million ≈ $71.00 Million |
€73.89 Million ≈ $86.38 Million |
-- |
About Nanoform Finland Plc
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) na… Read more